The first US participant has been dosed in Moderna’s Phase I study evaluating mRNA-4106, a novel pan-tumour antigen therapy candidate, in patients with advanced or metastatic solid tumours. The first dose was administered at START Center for Cancer Research (START) in San Antonio by Dr Amita Patnaik. Read More
Reece Armstrong examines the advances being made in identifying cell surface proteins and what this means for cancer drug discovery. There have been some landmark FDA approvals in recent years – but not everyone has picked up on the significance of its decision to green-light Merus’ lung and pancreatic cancer… Read More
On International Clinical Trials Day, Lars Erwig, Director of the Centre for Drug Development at Cancer Research UK, calls for an international approach to clinical trials. Launching a clinical trial for a new cancer treatment is a formidable challenge. For one thing, patient recruitment is arguably more difficult now than… Read More
A $1.25 million investment is driving the development of a new treatment for advanced and therapy-resistant prostate cancer at The University of Queensland. Based on research by Professor Greg Monteith from UQ’s School of Pharmacy and Pharmaceutical Sciences, the drug (QED-203) is being developed by the Queensland… Read More
Researchers at the University of Minnesota have completed a first-in-human clinical trial testing a CRISPR/Cas9 gene-editing technique to help the immune system fight advanced gastrointestinal (GI) cancers. The results, published in Lancet Oncology, show encouraging signs of safety and potential… Read More
DDW’s Megan Thomas hears from industry experts Daniel Veres, Turbine's Chief Scientific Officer & Co-Founder, as well as Ryan Jacobs, Business Development Manager at Astoriom, about AACR 2025. MT: What do you consider to be the key trends in cancer research? Daniel Veres: Key trends in cancer research include a… Read More
Leucid Bio has dosed the first patient in the Phase I AERIAL trial evaluating the safety and clinical activity of LEU011 in patients with refractory solid tumours. Initiation of the AERIAL trial follows the successful first close of the Series A1 financing of £7.2 ($9.51) million in February 2025, co-led… Read More
The Ministry of Health of the Republic of Indonesia and the CRUK Scotland Institute have entered into a landmark partnership to advance cancer research, build capacity in cancer care, and support evidence-based health policies through the signing of a Memorandum of Understanding (MoU). Dr Susanti Susanti, an… Read More
Czech biotechnology company, SOTIO, recently started preclinical development of its first two bispecific antibody drug conjugates (ADCs), which it says are “just the beginning” of what it has in store for its next-generation ADC pipeline. DDW’s Megan Thomas speaks with SOTIO’s Chief Scientific Officer, Martin Steegmaier, about the company’s pipeline. Read More
CAR-T cell therapy has revolutionised cancer treatment, offering life-changing outcomes for patients with haematological malignancies. Jean-Pierre Latere, PhD, CEO of EsoBiotec, discusses advances in in vivo engineering, which are poised to overcome manufacturing and cost barriers, making these therapies more accessible and expanding their potential applications. The landscape of cancer… Read More
SOTIO Biotech has presented preclinical data on two of its leading antibody-drug conjugate (ADC) candidates, SOT109 and SOT106, demonstrating strong anti-tumour activity and favourable tolerability profiles across multiple tumour models. The data shared at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL supports… Read More
Pheast Therapeutics has treated the first patient in its Phase I clinical trial evaluating PHST001, an anti-CD24 macrophage checkpoint inhibitor, in patients with advanced solid tumours. The study will enrol up to 80 patients with advanced relapsed and/or refractory solid tumours. The study’s primary objectives… Read More
DDW Editor Reece Armstrong takes a look at some of the recent activity in cancer research and examines where the biggest opportunities are in oncology. In January this year, researchers from the University of Toronto (UoT) and Insilico Medicine published a paper detailing how quantum computing combined with generative AI… Read More
The American Association of Cancer Research (AACR) Annual Meeting took place from 25-30 April at the McCormick Place Convention Center in Chicago, US. DDW’s Megan Thomas looks at key announcements, presentations and breakthroughs that took place. Presidential commentary On Sunday 27 April, attendees were welcomed at the Opening Ceremony by… Read More
Akiram Therapeutics, a Swedish biotech company specialising in targeted radiotherapy, has enrolled the first patient in the Phase I clinical trial of its drug candidate 177Lu-AKIR001. The trial is being conducted at Karolinska University Hospital, which also acts as the study sponsor, and marks an important milestone in Akiram’s efforts… Read More
Clasp Therapeutics has announced the dosing of the initial patient in the GUARDIAN-101 Phase I trial of CLSP-1025, the first tumour-specific TCE to enter clinical development. The company also presented non-clinical data for CLSP-1025 at the 2025 American Association for Cancer Research (AACR) Annual Meeting. … Read More
